CAR-T cells using PD-L1 as a CAR against non-small cell lung carcinoma (NSCLC) exerted anti-tumor cytotoxic effects against PD-L1-high and EGFR-mut NSCLC, leading to the recovery of PD-L1+ NSCLC patients [139]. This evidence concerns the gene CD274 and neoplasm.